ONL Therapeutics reports positive phase 1b data for xelafaslatide in GA | Optometry Times - Clinical News

Published on January 4, 2026
Xelafaslatide is a small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death.
Continue reading on website
Other news

Study maps thermal dynamics of glaucoma laser treatments | Optometry Times - Clinical News

January 4, 2026
The study evaluated thermal dynamics associated with CW-TSCPC and TLT using MicroPulse technology, such as temperature peak, exposure duration, and thermal spread in a simulated ciliary body using computer modeling.

Improved grading scales for oncology drugs causing ocular adverse events | Optometry Times - Clinical News

January 4, 2026
The grading scales were compiled with the goals of achieving conciseness and the ability to provide clear drug-dose-modification recommendations compared with the previous ocular CTCAE scale.